Dose-Sparing Romidepsin Regimens Promising in Cutaneous T-Cell LymphomaDose-Sparing Romidepsin Regimens Promising in Cutaneous T-Cell Lymphoma
Romidepsin regimens that employ less-frequent dosing can prolong remission in patients with some subtypes of cutaneous T-cell lymphoma (CTCL), according to a retrospective records review. Reuters Health Information
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
More News: Cancer & Oncology | Cutaneous T cell lymphoma | Health | Hematology | Lymphoma | T-cell Lymphoma